Genmab Partners With Incyte on Metastatic Colorectal Cancer Trial

Bitget2026/10/24 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab entered a clinical trial collaboration with Incyte and will conduct a Phase 1/2 study.
The study will test petosemtamab with INCB161734 and chemotherapy as first-line treatment for KRAS G12D-mutated metastatic colorectal cancer.
Incyte will co-fund the study and provide clinical supplies of INCB161734.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240700OMX_____CNEWS_EN_GNW1001279639_en) on October 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab Partners With Incyte on Metastatic Colorectal Cancer Trial

You may also like

Crypto prices